Literature DB >> 30017192

Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.

Mayu Takami1, Kazuhiro Katayama2, Kohji Noguchi1, Yoshikazu Sugimoto1.   

Abstract

FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) is a constitutively active mutant of FLT3 and causes 20%-30% of acute myeloid leukemia (AML) cases. FLT3-ITD upregulates the proviral integration site for Moloney murine leukemia virus 1 (PIM-1) expression and promotes the proliferation of AML cells. In this study, we investigated the role of protein kinase C (PKC)-mediated phosphorylation on the expression and function of PIM-1L. Drug screening in leukemia cell lines revealed that sotrastaurin (a PKC inhibitor) suppressed the proliferation of the FLT3-ITD-positive AML cell line MV4-11 but not of K562, HL60, or KG-1a cells, similar to SGI-1776 (a PIM-1/FLT3 inhibitor) and quizartinib (an FLT3 inhibitor). Sotrastaurin decreased the expression of pro-survival protein myeloid cell leukemia (MCL-1) and the phosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), both of which are downstream effectors of PIM-1. PKCα directly phosphorylated Ser65 of PIM-1L, which is a long isoform of PIM-1. The PKCα-mediated phosphorylation stabilized PIM-1L. The phosphorylation-mimicked mutant, PIM-1L-S65D, was more stable and showed higher kinase activity than PIM-1L-S65A. Expression of PIM-1L-wildtype or -S65D reduced sotrastaurin-mediated apoptosis and growth inhibition in MV4-11 transfectants. These results suggest that PKCα directly upregulates PIM-1L, resulting in promotion of the survival and proliferation of AML cells.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3-ITD; PIM-1L; PKCα; p27(KIP1)

Mesh:

Substances:

Year:  2018        PMID: 30017192     DOI: 10.1016/j.bbrc.2018.07.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  The specific PKC-α inhibitor chelerythrine blunts costunolide-induced eryptosis.

Authors:  Mehrdad Ghashghaeinia; Pavla Koralkova; Daniela Giustarini; Renata Mojzikova; Birgit Fehrenbacher; Peter Dreischer; Martin Schaller; Ulrich Mrowietz; Antonio Martínez-Ruiz; Thomas Wieder; Vladimir Divoky; Ranieri Rossi; Florian Lang; Martin Köberle
Journal:  Apoptosis       Date:  2020-10       Impact factor: 4.677

2.  Human erythrocytes, nuclear factor kappaB (NFκB) and hydrogen sulfide (H2S) - from non-genomic to genomic research.

Authors:  Mehrdad Ghashghaeinia; Ulrich Mrowietz
Journal:  Cell Cycle       Date:  2021-09-24       Impact factor: 4.534

3.  Causal reasoning over knowledge graphs leveraging drug-perturbed and disease-specific transcriptomic signatures for drug discovery.

Authors:  Daniel Domingo-Fernández; Yojana Gadiya; Abhishek Patel; Sarah Mubeen; Daniel Rivas-Barragan; Chris W Diana; Biswapriya B Misra; David Healey; Joe Rokicki; Viswa Colluru
Journal:  PLoS Comput Biol       Date:  2022-02-25       Impact factor: 4.475

4.  GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells.

Authors:  Xuan Chu; Liang Zhong; Lihua Yu; Ling Xiong; Jian Li; Wenran Dan; Jiao Ye; Chen Liu; Xu Luo; Beizhong Liu
Journal:  Cancer Cell Int       Date:  2020-06-03       Impact factor: 5.722

5.  Dual Targeting of Stromal Cell Support and Leukemic Cell Growth by a Peptidic PKC Inhibitor Shows Effectiveness against B-ALL.

Authors:  Paola Fernanda Ruiz-Aparicio; Natalia-Del Pilar Vanegas; Gloria Inés Uribe; Paola Ortiz-Montero; Camila Cadavid-Cortés; Jimmy Lagos; Jessica Flechas-Afanador; Adriana Linares-Ballesteros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

6.  Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.

Authors:  Muskan Floren; Sebastian Restrepo Cruz; Christina M Termini; Kristopher D Marjon; Keith A Lidke; Jennifer M Gillette
Journal:  Oncogene       Date:  2020-03-19       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.